Centerpoint Advisory Group
MAIA icon

Centerpoint Advisory Group’s MAIA Biotechnology MAIA Stock Holding History

Centerpoint Advisory Group’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.6K Hold
15,730
– – 0.01% 120
2026
Q2 		$22.7K Hold
15,730
– – 0.01% 117
2026
Q1 		$22K Hold
15,730
– – 0.02% 108
2025
Q4 		$24.1K Hold
15,730
– – 0.02% 107
2025
Q3 		$24.2K Hold
15,730
– – 0.02% 108
2025
Q2 		$28.3K Buy
+15,730
New +$28.2K 0.02% 100

Other funds holding MAIA

PVG Asset Management
PVG Asset Management Golden, Colorado $147M AUM 52.72% 1-Year Est. Return
Lazari Capital Management
Lazari Capital Management Woodland Hills, California $339M AUM 25.58% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Daytona Street Capital
Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Centerpoint Advisory Group's MAIA Position: Q3 2026 in Review

Centerpoint Advisory Group held its MAIA Biotechnology (MAIA) position steady in Q3 2026 at 15,730 shares worth $18.6K. The position accounts for 0.01% of the portfolio, ranked #120.

Centerpoint Advisory Group first reported a position in MAIA in Q2 2025 and has held it in 6 quarters since. The position peaked at $28.3K in Q2 2025. 7 funds tracked by Wall St. Rank hold MAIA as of Q3 2026.

  • Centerpoint Advisory Group held 15,730 shares of MAIA Biotechnology worth $18.6K as of Q3 2026.
  • Centerpoint Advisory Group left its MAIA Biotechnology share count unchanged in Q3 2026.
  • MAIA Biotechnology made up 0.01% of Centerpoint Advisory Group's portfolio in Q3 2026, its #120 holding.
  • Centerpoint Advisory Group first reported a position in MAIA Biotechnology in Q2 2025 and has held it in 6 quarters since.
  • Centerpoint Advisory Group's MAIA Biotechnology position peaked at $28.3K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q3 2026.

Based on Centerpoint Advisory Group's 13F filing for Q3 2026, filed 23 Oct 2026.